FDA Guides Makers on Faster Weight-Loss Device Approvals
Published Date: 3/13/2026
Notice
Summary
The FDA just released new guidance to help companies get their weight-loss medical devices approved faster and safer. This affects anyone making devices that claim to help with weight loss, with clear steps on testing and proving benefits before selling. The guidance is effective now, so expect smoother reviews and smarter investments in device development.
Analyzed Economic Effects
4 provisions identified: 4 benefits, 0 costs, 0 mixed.
Final Guidance for Weight-Loss Devices
On March 13, 2026, the FDA published a final guidance titled "Medical Devices with Indications Associated with Weight Loss--Premarket Considerations." The guidance gives recommendations on non-clinical testing and clinical study design to support premarket submissions for devices that claim weight loss or obesity treatment.
Specific Trial Design Clarifications Included
The final guidance explicitly discusses use of sham controls, statistical analysis using modified intent-to-treat populations, and inclusion of patient-reported outcomes as part of benefit-risk evaluation. It also references FDA's Q-Submission Program as a way to request feedback on proposed clinical study design.
Intended to Speed and Standardize Reviews
FDA states the recommendations reflect current review practices and are "intended to promote consistency and facilitate efficient review" of premarket submissions for weight-loss devices. The guidance consolidates two prior draft guidances into one final document to ease use.
No New Paperwork Collections Listed
The guidance states it contains no new collection of information under the Paperwork Reduction Act and refers to previously approved FDA collections with OMB control numbers such as 0910-0120, 0910-0231, 0910-0078, 0910-0844, 0910-0756, 0910-0485, 0910-0073, 0910-0130, and 0910-0119. Those existing approvals continue to apply.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16296, Substances Generally Recognized as Safe
The Food and Drug Administration (FDA or we) is proposing to require the submission of generally recognized as safe (GRAS) notices for the use of a human or animal food substance purported to be GRAS under the conditions of its intended use under the Federal Food, Drug, and Cosmetic Act (FD&C Act).
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-16728, Gastroenterology-Urology Devices; Reclassification of Diagnostic Endoscopic Light Source Systems To Be Renamed Cystoscopic Systems Intended as an Aid for Detection of Bladder Cancer
The Food and Drug Administration (FDA) is proposing to reclassify diagnostic endoscopic light source systems (product code OAY), which are postamendments class III devices, from class III (premarket approval) into class II (special controls), subject to premarket notification. FDA is also proposing a new device classification regulation with the name "Cystoscopic system intended as an aid for detection of bladder cancer," along with special controls that FDA believes are necessary to provide a reasonable assurance of the safety and effectiveness of these devices.
2026-16712, Agency Information Collection Activities; Proposed Collection; Comment Request; Imports and Electronic Import Entries
The FDA wants your thoughts on how they collect info about imports and electronic import entries. If you’re involved in importing goods, this could affect you! They’re asking for comments by October 16, 2026, to help improve the process without adding extra costs or hassle.
2026-16727, Hematology and Pathology Devices; Reclassification of In Situ Hybridization Test Systems for Use With a Corresponding Approved Oncology Therapeutic Product
The Food and Drug Administration (FDA, the Agency, or we) is issuing a final order reclassifying in situ hybridization (ISH) test systems indicated for use with a corresponding approved oncology therapeutic product (product codes NYQ, MVD, OWE, and PNK), all postamendments class III (premarket approval) devices, into class II (special controls), subject to premarket notification. FDA is also establishing a new device classification regulation, along with the special controls that are necessary to provide a reasonable assurance of safety and effectiveness of this device type.
Previous / Next Documents
Previous: 2026-04917, Agency Information Collection Activities: Request for Comments for a New Information Collection
The Federal Highway Administration wants your thoughts on a new way to collect info about training programs for highway construction workers. This helps make sure workers get the right skills for new tech and growing job demands. If you’re involved in construction or training, you can comment by May 12, 2026—no cost to you, just your ideas!
Next: 2026-04920, Submission for OMB Review; Comment Request
The Department of Defense wants your feedback on a new form for businesses and individuals asking for military help with productions. They’re collecting info to make sure requests follow rules and support is available. You’ve got until April 13, 2026, to share your thoughts—no money changes, just a quick 45-minute form if you apply.